W-18 was commonly reported to be an [[opioid]] in the popular press in the 2010s, which was later revealed not to be correct.<ref name="calgaryherald">{{cite web | url=http://calgaryherald.com/news/local-news/health-canada-statements-on-w-18-misleading-potentially-wrong-experts-warn | title=Health Canada statements on W-18 misleading, potentially wrong, experts warn | publisher=Postmedia Network Inc. | work=Calgary Herald | date=1 June 2016 | accessdate=22 June 2016 | author=Southwick, Reid}}</ref><ref>{{cite web | url=https://news.vice.com/article/canadas-ban-on-ultra-potent-drug-w-18-could-make-things-worse | title=Canada's Ban on Ultra-Potent Drug W-18 Could Make Things Worse | publisher=Vice | date=2 June 2016 | author=Rachel Browne}}</ref><ref name="Roth"/><ref name="Roth">{{cite journal|first1=Xi-Ping|last1=Huang|first2=Tao|last2=Che|first3=Thomas|last3=Mangano|first4=Valerie Le|last4=Rouzic|title=Pharmacology of W-18 and W-15|url=http://biorxiv.org/content/early/2016/07/24/065623|journal=bioRxiv|date=24 July 2016|doi=10.1101/065623|first5=Ying-Xian|last5=Pan|first6=Susruta|last6=Majumdar|first7=Michael|last7=Cameron|first8=Michael|last8=Bauman|first9=Gavril|last9=Pasternak|first10=Bryan L.|last10=Roth}}</ref> W-18 was found to obtain weak activity at both [[sigma receptor]]s and the [[translocator protein]] (peripheral benzodiazepine receptor).<ref name="Roth"/> It also inhibits [[hERG]] binding, an important antitarget in drug discovery, which possibly causes cardiovascular side-effects.<ref name="Roth"/>
